Developer docs
API playgroundTry for free, no card

Search company profiles

Laboratoires Chemineau

Full company profile

uuid000n95q

Namestring
Laboratoires Chemineau
Legal namestring
Laboratoires Chemineau
Websiteurl
chemineau.com
Company typeenum
Private
Founded yearint
1947
Descriptiontext

Laboratoires Chemineau is a private French CDMO founded in 1947 and headquartered in Vouvray. It develops and manufactures topical, liquid, semi-solid, spray, and aerosol products for pharmaceutical companies, healthcare brands, cosmetics companies, and dietary-supplement businesses, with therapeutic emphasis on dermatology, women's health, pain relief, and respiratory/ORL applications. The company reports 320 collaborators, 27 production lines, 60 million units produced annually, and 300+ product references; 87% of revenue is attributed to pharmaceutical products and medical devices. It operates as a wholly owned subsidiary of ANJAC Group.

Chemineau's technical offer includes Emulpro, a patented next-generation micro-gellified oil-in-water emulsion platform with fewer than 10 INCI ingredients and 0.1–1% surfactant, plus a contamination-free process for BOV aerosols and metered-dose sprays. It has opened an ultra-clean GMP unit for R&D, pilot, and Phase I–III clinical batches, including rare-disease treatments, highly active materials at OEB6, liquid-to-semi-solid forms, and multiple primary-packaging options.

It offers full-service or à la carte engagements spanning pre-formulation, formulation, stability studies, development, industrial transfer, regulatory support, analytical method development and validation, clinical batches, and industrial/commercial production. Go-to-market is direct enterprise selling to business customers; pricing is not publicly disclosed and appears to be negotiated per project.

Short descriptiontext

French CDMO developing and manufacturing topical, dermatological, women’s health, pain-relief, and respiratory/ORL products for pharmaceutical companies, healthcare brands, cosmetics companies, and dietary-supplement businesses, from formulation through clinical and commercial production.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersVouvray, France
HQ citystring
Vouvray
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical CDMO services, topical product manufacturing, ORL pharmaceutical formulations, contract development manufacturing, aerosol and spray manufacturing
Industry3 codes
1Drug Substance–Drug Product Integrated CDMO
CodeHLAGABAGPrimaryYes
2Clinical Trial Material (CTM) Manufacturing & Supply CDMO
CodeHLAGABAKPrimaryNo
3Small-Molecule API & Intermediates CDMO
CodeHLAGABAAPrimaryNo
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Pharmaceutical CDMO (Contract Development and Manufacturing)
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1CDMO Manufacturing Services
TypeProfessional Services
Description

Contract development and manufacturing services for pharmaceutical products, medical devices, cosmetics, and dietary supplements in liquid, semi-solid, spray, and aerosol forms. Revenue generated through full-service or à la carte manufacturing engagements.

anjac.com
2Formulation and Development Services
TypeProfessional Services
Description

Pre-formulation, formulation, stability studies, development, industrial transposition, technology transfer, regulatory support, and analytical method development and validation services.

anjac.com
3Clinical Batch Production
TypeProfessional Services
Description

Production of clinical trial batches (Phase I, II, III) for R&D and pilot purposes, including rare disease treatments.

anjac.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Supply Chain, Infrastructure, Technology or R&D, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Emulpro
Description

Patented next-generation platform that stabilizes actives while ensuring optimal tolerance for skin and mucous membranes in health and cosmetic applications. Micro gelified oil-in-water emulsion, natural and customized (less than 10 INCI ingredients), with very low surfactant content (0.1-1%), offering an ultra-tolerant base.

anjac.com
Core offering1 text field

Laboratoires Chemineau is a French contract development and manufacturing organization (CDMO) providing full-service or à la carte manufacturing of topical pharmaceutical products (creams, gels, emulsions) and ORL (ear, nose, throat) products including nasal sprays, throat sprays, and aerosols. Its offering spans pre-formulation, formulation, stability studies, industrial transposition, technology transfer, regulatory support, clinical batch production, and commercial manufacturing across dermatology, women's health, pain relief, and respiratory therapeutic areas. The company operates 27 production lines producing 60 million units per year.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Laboratoires Chemineau operates as a CDMO (Contract Development and Manufacturing Organization) offering full-service or à la carte pharmaceutical manufacturing. Their core offerings include Emulpro (a patented micro-gelled oil-in-water emulsion platform), clinical batch production services, and contamination-free BOV/spray manufacturing technology. The company produces a comprehensive portfolio of topical and respiratory/ORL products organized into four main therapeutic areas: Dermatology (antibiotics, antiseptics, antifungals, anesthetics, anti-acne, anti-psoriasis, wound care), Women's Health (vaginal treatments, hormone therapy), Pain Relief (topical NSAIDs, hot/cold CBD/essential oil-based analgesics), and Respiratory/ORL (nasal hygiene, seawater, corticosteroids, throat treatments). Their services span pre-formulation, formulation, stability studies, industrial transposition, regulatory support, and commercial production across liquid, semi-solid, spray, and aerosol forms.

Product and service4 records
1Emulpro Galenic Platform
CategoryTechnology platform
Description

Proprietary patented formulation platform for developing dermatological, vaginal, and nasal pharmaceutical and cosmetic solutions with enhanced skin and mucous membrane tolerance and under 10 INCI ingredients.

2Clinical Batch Production Services
CategoryManufacturing service
Description

Dedicated GMP ultra-clean unit for production of R&D, pilot, and clinical batches (Phase I, II, III), including rare disease medications in liquid to semi-solid forms with highly active materials (OEB6) and various primary packaging options.

3BOV Aerosol and Metered-Dose Spray Manufacturing
CategoryManufacturing technology
Description

Contamination-free manufacturing process for BOV aerosols and metered-dose sprays ensuring formula stability and packaging functionality, ideal for preservative-free products with maximum safety and quality.

4Full-Service CDMO Development and Manufacturing
CategoryManufacturing service
Description

End-to-end contract development and manufacturing services for pharmaceutical products, medical devices, cosmetics, and dietary supplements in liquid, semi-solid, spray, and aerosol forms, available as full-service or à la carte engagements.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierParent CompanyTypeOthers
Description

Laboratoires Chemineau is part of the ANJAC Group, a health and beauty company conglomerate. ANJAC Groups brings together complementary pharmaceutical and cosmetic manufacturing capabilities under one umbrella.

Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Swedish-headquartered European CDMO operating multiple semisolid/liquid and aerosol manufacturing sites with similar topical and inhalation capabilities, directly comparable to Chemineau's service portfolio.

TypeDirect peer
Description

Portugal-based CDMO specializing in complex formulations, sprays, and highly potent compounds – directly overlapping with Chemineau's complex galenics, highly active, and nasal spray expertise.

TypeDirect peer
Description

French pharmaceutical and cosmetic CDMO with comparable topical, liquid, and aerosol manufacturing capabilities across health and beauty – a direct French competitor to Chemineau.

TypeDirect peer
Description

French pharmaceutical CDMO focused on solid, liquid, and semi-solid dosage forms with deep European customer relationships – competes head-to-head with Chemineau for French pharma contract manufacturing work.

TypeBroad incumbent
Description

Large global CDMO with established topical, softgel, and clinical supply services – a broad incumbent whose scale and breadth overlap Chemineau's offerings across multiple customers and programs.

TypeBroad incumbent
Description

European CDMO group offering solid, semi-solid, and liquid manufacturing across multiple sites – broader portfolio player competing with Chemineau for topical and specialty pharma contracts.

TypeDirect peer
Description

European pharmaceutical CDMO with sterile, solid, semi-solid and clinical services targeted to mid-sized pharma – operates as a direct peer for outsourced topical and ORL production.

TypeBroad incumbent
Description

European CDMO with strength in complex APIs and highly potent drug products, including semi-solid and topical forms – broader incumbent that competes for the highly active (OEB-classified) work Chemineau targets.

TypeBroad incumbent
Description

Global drug-delivery device and component supplier (spray pumps, valves, BOV systems) closely tied to nasal/aerosol drug product manufacturing – adjacent incumbent with comparable spray/aerosol expertise to Chemineau's BOV and metered-dose offerings.

TypeDirect peer
Description

Canadian-headquartered CDMO specializing in semi-solid and liquid pharmaceutical manufacturing for dermatology and topical products – a close specialty peer focused on the same niche topical formulations as Chemineau.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Laboratoires Chemineau

Pharmaceutical CDMO (Contract Development and Manufacturing)chemineau.com

French CDMO developing and manufacturing topical, dermatological, women’s health, pain-relief, and respiratory/ORL products for pharmaceutical companies, healthcare brands, cosmetics companies, and dietary-supplement businesses, from formulation through clinical and commercial production.

What Laboratoires Chemineau does

Laboratoires Chemineau is a private French CDMO founded in 1947 and headquartered in Vouvray. It develops and manufactures topical, liquid, semi-solid, spray, and aerosol products for pharmaceutical companies, healthcare brands, cosmetics companies, and dietary-supplement businesses, with therapeutic emphasis on dermatology, women's health, pain relief, and respiratory/ORL applications. The company reports 320 collaborators, 27 production lines, 60 million units produced annually, and 300+ product references; 87% of revenue is attributed to pharmaceutical products and medical devices. It operates as a wholly owned subsidiary of ANJAC Group.

Chemineau's technical offer includes Emulpro, a patented next-generation micro-gellified oil-in-water emulsion platform with fewer than 10 INCI ingredients and 0.1–1% surfactant, plus a contamination-free process for BOV aerosols and metered-dose sprays. It has opened an ultra-clean GMP unit for R&D, pilot, and Phase I–III clinical batches, including rare-disease treatments, highly active materials at OEB6, liquid-to-semi-solid forms, and multiple primary-packaging options.

It offers full-service or à la carte engagements spanning pre-formulation, formulation, stability studies, development, industrial transfer, regulatory support, analytical method development and validation, clinical batches, and industrial/commercial production. Go-to-market is direct enterprise selling to business customers; pricing is not publicly disclosed and appears to be negotiated per project.

Laboratoires Chemineau firmographics

Firmographics
Name
Laboratoires Chemineau
Legal name
Laboratoires Chemineau
Website
https://chemineau.com
Company type
Private
Founded year
1947
Operating status
Operating
Headcount range
51–100 employees
Short description
French CDMO developing and manufacturing topical, dermatological, women’s health, pain-relief, and respiratory/ORL products for pharmaceutical companies, healthcare brands, cosmetics companies, and dietary-supplement businesses, from formulation through clinical and commercial production.
Ownership category
akta.pro rank

Laboratoires Chemineau industry classification

Industry
Product category
Pharmaceutical CDMO (Contract Development and Manufacturing)
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro primary industry
Drug Substance–Drug Product Integrated CDMO (HLAGABAG)
akta.pro secondary industries
Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Small-Molecule API & Intermediates CDMO (HLAGABAA)

Keywords

  • Pharmaceutical CDMO services
  • Topical product manufacturing
  • ORL pharmaceutical formulations
  • Contract development manufacturing
  • Aerosol and spray manufacturing

Where Laboratoires Chemineau is headquartered

Location

Headquarters

HQ city
Vouvray
HQ country
France
HQ region
Europe

Offices1 record

Markets served

Laboratoires Chemineau business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Supply Chain, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

  1. CDMO Manufacturing Services: Contract development and manufacturing services for pharmaceutical products, medical devices, cosmetics, and dietary supplements in liquid, semi-solid, spray, and aerosol forms. Revenue generated through full-service or à la carte manufacturing engagements.
  2. Formulation and Development Services: Pre-formulation, formulation, stability studies, development, industrial transposition, technology transfer, regulatory support, and analytical method development and validation services.
  3. Clinical Batch Production: Production of clinical trial batches (Phase I, II, III) for R&D and pilot purposes, including rare disease treatments.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Laboratoires Chemineau product offering

Product offering

Core offering

Laboratoires Chemineau is a French contract development and manufacturing organization (CDMO) providing full-service or à la carte manufacturing of topical pharmaceutical products (creams, gels, emulsions) and ORL (ear, nose, throat) products including nasal sprays, throat sprays, and aerosols. Its offering spans pre-formulation, formulation, stability studies, industrial transposition, technology transfer, regulatory support, clinical batch production, and commercial manufacturing across dermatology, women's health, pain relief, and respiratory therapeutic areas. The company operates 27 production lines producing 60 million units per year.

Product overview

Laboratoires Chemineau operates as a CDMO (Contract Development and Manufacturing Organization) offering full-service or à la carte pharmaceutical manufacturing. Their core offerings include Emulpro (a patented micro-gelled oil-in-water emulsion platform), clinical batch production services, and contamination-free BOV/spray manufacturing technology. The company produces a comprehensive portfolio of topical and respiratory/ORL products organized into four main therapeutic areas: Dermatology (antibiotics, antiseptics, antifungals, anesthetics, anti-acne, anti-psoriasis, wound care), Women's Health (vaginal treatments, hormone therapy), Pain Relief (topical NSAIDs, hot/cold CBD/essential oil-based analgesics), and Respiratory/ORL (nasal hygiene, seawater, corticosteroids, throat treatments). Their services span pre-formulation, formulation, stability studies, industrial transposition, regulatory support, and commercial production across liquid, semi-solid, spray, and aerosol forms.

Differentiator

Problem solved

Functional benefit

Brands

  • Emulpro: Patented next-generation platform that stabilizes actives while ensuring optimal tolerance for skin and mucous membranes in health and cosmetic applications. Micro gelified oil-in-water emulsion, natural and customized (less than 10 INCI ingredients), with very low surfactant content (0.1-1%), offering an ultra-tolerant base.

Products and services

  • Emulpro Galenic Platform Proprietary patented formulation platform for developing dermatological, vaginal, and nasal pharmaceutical and cosmetic solutions with enhanced skin and mucous membrane tolerance and under 10 INCI ingredients.
  • Clinical Batch Production Services Dedicated GMP ultra-clean unit for production of R&D, pilot, and clinical batches (Phase I, II, III), including rare disease medications in liquid to semi-solid forms with highly active materials (OEB6) and various primary packaging options.
  • BOV Aerosol and Metered-Dose Spray Manufacturing Contamination-free manufacturing process for BOV aerosols and metered-dose sprays ensuring formula stability and packaging functionality, ideal for preservative-free products with maximum safety and quality.
  • Full-Service CDMO Development and Manufacturing End-to-end contract development and manufacturing services for pharmaceutical products, medical devices, cosmetics, and dietary supplements in liquid, semi-solid, spray, and aerosol forms, available as full-service or à la carte engagements.

Companies that use Laboratoires Chemineau

Customer profile

Segments4 records

Ideal customer profiles3 records

Laboratoires Chemineau technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Laboratoires Chemineau partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • ANJAC Groupparent companyOthersLaboratoires Chemineau is part of the ANJAC Group, a health and beauty company conglomerate. ANJAC Groups brings together complementary pharmaceutical and cosmetic manufacturing capabilities under one umbrella.

Scale indicators7 records

Recent moves3 records

Expansion highlights6 records

Laboratoires Chemineau competitors and assessment

Company assessment

Direct peers

  • Recipharm: Swedish-headquartered European CDMO operating multiple semisolid/liquid and aerosol manufacturing sites with similar topical and inhalation capabilities, directly comparable to Chemineau's service portfolio.
  • Hovione: Portugal-based CDMO specializing in complex formulations, sprays, and highly potent compounds – directly overlapping with Chemineau's complex galenics, highly active, and nasal spray expertise.
  • Fareva: French pharmaceutical and cosmetic CDMO with comparable topical, liquid, and aerosol manufacturing capabilities across health and beauty – a direct French competitor to Chemineau.
  • Delpharm: French pharmaceutical CDMO focused on solid, liquid, and semi-solid dosage forms with deep European customer relationships – competes head-to-head with Chemineau for French pharma contract manufacturing work.
  • NextPharma: European pharmaceutical CDMO with sterile, solid, semi-solid and clinical services targeted to mid-sized pharma – operates as a direct peer for outsourced topical and ORL production.
  • Pillar5 Pharma: Canadian-headquartered CDMO specializing in semi-solid and liquid pharmaceutical manufacturing for dermatology and topical products – a close specialty peer focused on the same niche topical formulations as Chemineau.

Broad incumbents

  • Catalent: Large global CDMO with established topical, softgel, and clinical supply services – a broad incumbent whose scale and breadth overlap Chemineau's offerings across multiple customers and programs.
  • Aenova Group: European CDMO group offering solid, semi-solid, and liquid manufacturing across multiple sites – broader portfolio player competing with Chemineau for topical and specialty pharma contracts.
  • CordenPharma: European CDMO with strength in complex APIs and highly potent drug products, including semi-solid and topical forms – broader incumbent that competes for the highly active (OEB-classified) work Chemineau targets.
  • Aptar Pharma: Global drug-delivery device and component supplier (spray pumps, valves, BOV systems) closely tied to nasal/aerosol drug product manufacturing – adjacent incumbent with comparable spray/aerosol expertise to Chemineau's BOV and metered-dose offerings.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Laboratoires Chemineau social profiles

Digital presence

Laboratoires Chemineau compliance and trust

Trust signal

Compliance4 records

Laboratoires Chemineau financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Laboratoires Chemineau leadership team

Management profile

Number of profiles

Laboratoires Chemineau funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Laboratoires Chemineau M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Laboratoires Chemineau

What does Laboratoires Chemineau do?

Laboratoires Chemineau is a French contract development and manufacturing organization (CDMO) providing full-service or à la carte manufacturing of topical pharmaceutical products (creams, gels, emulsions) and ORL (ear, nose, throat) products including nasal sprays, throat sprays, and aerosols. Its offering spans pre-formulation, formulation, stability studies, industrial transposition, technology transfer, regulatory support, clinical batch production, and commercial manufacturing across dermatology, women's health, pain relief, and respiratory therapeutic areas. The company operates 27 production lines producing 60 million units per year.

Is Laboratoires Chemineau a public or private company?

Laboratoires Chemineau is a private company. It is classified as corporate owned and is currently operating.

When was Laboratoires Chemineau founded?

Laboratoires Chemineau was founded in 1947. It employs 51 to 100 people.

Where is Laboratoires Chemineau based?

Laboratoires Chemineau is headquartered in Vouvray, France, in the Europe region.

How does Laboratoires Chemineau make money?

Three revenue lines are on record. CDMO Manufacturing Services are the primary driver. The others are formulation and Development Services and clinical Batch Production.

Who are Laboratoires Chemineau's main competitors?

Direct peers on record are Recipharm, Hovione, Fareva, Delpharm, NextPharma and Pillar5 Pharma. Broad incumbents are Catalent, Aenova Group, CordenPharma and Aptar Pharma.

Does Laboratoires Chemineau have an API?

No public API is recorded for Laboratoires Chemineau.

What industry is Laboratoires Chemineau in?

Laboratoires Chemineau's product category is Pharmaceutical CDMO (Contract Development and Manufacturing). Its primary akta.pro industry code is HLAGABAG, Drug Substance–Drug Product Integrated CDMO, with a secondary code of HLAGABAK, Clinical Trial Material (CTM) Manufacturing & Supply CDMO. Its NAICS code is 325412 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales